Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA

Journal of Virology

Volumn 75, Issue 10, 2001, Pages 4752-4760

  Gerber, S ^a   Lane, C ^a   Brown, D M ^a   Lord, E ^a   Dilorenzo, M ^a   Clements, J D ^a   Rybicki, E ^a   Williamson, A L ^a   Rose, R C ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DOSE RESPONSE; ESCHERICHIA COLI; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS PARTICLE; VIRUS RECOMBINANT; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BACTERIAL TOXINS; CAPSID PROTEINS; CPG ISLANDS; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; VACCINES, SYNTHETIC; VAGINA; VIRAL VACCINES; VIRION;

EID: 0035027908     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.10.4752-4760.2001     Document Type: Article

References (49)

1. Reducing the risk of unsafe injections in immunization programmes: Financial and operational implications of various injection technologies
2. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions
3. Papillomavirus
4. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
5. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection
6. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus-like particle IgG concentration
7. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis
8. New approaches to mucosal immunization
9. Functional mapping of protective domains and epitopes in the rotavirus VP6 protein
10. Assembled baculovirus-expressed human papillomavirus type II L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies
11. Human papillomavirus types 6 and II have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
12. Human pathogenic papillomavirus types: An update
13. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
14. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes
15. Immunological analyses of human papillomavirus capsids
16. Detection of immunoglobulin M (IgM), IgA, and IgG Norwalk virus-specific antibodies by indirect enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in adult volunteers challenged with Norwalk virus
17. Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain
18. Self-assembly of human papillomavirus type I capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins
19. A Toll-like receptor recognizes bacterial DNA
20. Future vaccines and a global perspective
21. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
22. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization
23. CpG motifs in bacterial DNA trigger direct B-cell activation
24. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice
25. CpG DNA as mucosal adjuvant
26. Mucosal vaccines: An overview
27. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
28. Mucosal immunity to viruses
29. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice
30. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice
31. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge
32. Anthropological perspectives on injections: A review
33. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype
34. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition
35. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles
36. Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of viruslike particles
37. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies
38. Human pappillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera
39. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies
40. Papillomavirus-like particle vaccines for cervical cancer
41. Papillomaviruses
42. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
43. Generation and neutralization of pseudovirions of human papillomavirus type 33
44. Bacterial CpG DNA activates immune cells to signal infectious danger
45. Immunostimulatory oligode-oxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms
46. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16
47. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types
48. Papillomaviruses in human cancers